ATE237359T1 - Zyklodextrin-zusammensetzung enthaltend ein avermectin- oder ein milbemycin-derivat - Google Patents
Zyklodextrin-zusammensetzung enthaltend ein avermectin- oder ein milbemycin-derivatInfo
- Publication number
- ATE237359T1 ATE237359T1 AT98310562T AT98310562T ATE237359T1 AT E237359 T1 ATE237359 T1 AT E237359T1 AT 98310562 T AT98310562 T AT 98310562T AT 98310562 T AT98310562 T AT 98310562T AT E237359 T1 ATE237359 T1 AT E237359T1
- Authority
- AT
- Austria
- Prior art keywords
- avermectin
- composition containing
- cyclodextrin composition
- milbemycin derivative
- milbemycin
- Prior art date
Links
- 239000005660 Abamectin Substances 0.000 title abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 2
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical class C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 title abstract 2
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Chemical class COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 title abstract 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9801109.1A GB9801109D0 (en) | 1998-01-20 | 1998-01-20 | Cyclodextrin compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE237359T1 true ATE237359T1 (de) | 2003-05-15 |
Family
ID=10825529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98310562T ATE237359T1 (de) | 1998-01-20 | 1998-12-22 | Zyklodextrin-zusammensetzung enthaltend ein avermectin- oder ein milbemycin-derivat |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20020032161A1 (de) |
| EP (1) | EP0930077B1 (de) |
| JP (2) | JPH11255646A (de) |
| AT (1) | ATE237359T1 (de) |
| BR (1) | BR9900114A (de) |
| CA (1) | CA2259699A1 (de) |
| DE (1) | DE69813496T2 (de) |
| DK (1) | DK0930077T3 (de) |
| ES (1) | ES2194279T3 (de) |
| GB (1) | GB9801109D0 (de) |
| PT (1) | PT930077E (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7091192B1 (en) * | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
| BRPI0200751B1 (pt) * | 2002-02-06 | 2018-10-23 | Univ Minas Gerais | complexos de inclusão de benzaldeído semicabazona em ciclodextrinas e seu método de preparação |
| KR101476067B1 (ko) | 2002-09-06 | 2014-12-23 | 인설트 테라페틱스, 인코퍼레이티드 | 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체 |
| WO2005014010A1 (en) * | 2003-07-24 | 2005-02-17 | Eli Lilly And Company | Pharmaceutical composition comprising gemcitabine and cyclodextrines |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| EP2219643B1 (de) | 2007-11-15 | 2012-05-16 | Novartis AG | Anthelmintische paste mit praziquantel, einem makrolid-lacton, cyclodextrin und einem verdickungsmittel |
| CN102781237A (zh) * | 2009-11-23 | 2012-11-14 | 天蓝制药公司 | 用于传递治疗剂的基于环糊精的聚合物 |
| US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| CN104208017A (zh) * | 2013-05-29 | 2014-12-17 | 镇江威特药业有限责任公司 | 一种伊维菌素溶液及其制备方法 |
| FR3042412A1 (fr) * | 2015-10-14 | 2017-04-21 | Biotopic Pharmaceuticals | Formulation pharmaceutique stabilisee et prete a l'emploi d'ivermectine dans le traitement des parasitoses humaines et animales |
| JP2019535827A (ja) * | 2016-11-16 | 2019-12-12 | アイビタ バイオメディカル インコーポレイテッド | 細胞膜結合シグナル伝達因子の使用 |
| US20200390678A1 (en) | 2017-11-16 | 2020-12-17 | Aivita Biomedical, Inc. | Use of cell membrane-bound signaling factors |
| CN108982883A (zh) * | 2018-07-16 | 2018-12-11 | 上海海洋大学 | 一种预测鲜切生菜货架期模型 |
| WO2022034226A1 (en) * | 2020-08-14 | 2022-02-17 | Universidad De Navarra | Avermectin and milbemycin compositions for inhalation |
| US11077134B1 (en) * | 2020-11-10 | 2021-08-03 | Mountain Valley Md Inc | Water dissolvable macrocyclic lactone cyclodextrin complexes |
| US11253533B1 (en) * | 2020-11-10 | 2022-02-22 | Mountain Valley Md Inc | Water dissolvable macrocyclic lactone cyclodextrin complexes |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0750907B1 (de) * | 1995-06-30 | 2002-03-20 | American Cyanamid Company | Stabile Makrolide und Makrolide Imptstoff-Zusammensetzungen |
-
1998
- 1998-01-20 GB GBGB9801109.1A patent/GB9801109D0/en not_active Ceased
- 1998-12-22 ES ES98310562T patent/ES2194279T3/es not_active Expired - Lifetime
- 1998-12-22 AT AT98310562T patent/ATE237359T1/de not_active IP Right Cessation
- 1998-12-22 DK DK98310562T patent/DK0930077T3/da active
- 1998-12-22 EP EP98310562A patent/EP0930077B1/de not_active Expired - Lifetime
- 1998-12-22 PT PT98310562T patent/PT930077E/pt unknown
- 1998-12-22 DE DE69813496T patent/DE69813496T2/de not_active Expired - Fee Related
-
1999
- 1999-01-11 JP JP11003730A patent/JPH11255646A/ja active Pending
- 1999-01-18 CA CA002259699A patent/CA2259699A1/en not_active Abandoned
- 1999-01-19 BR BR9900114-4A patent/BR9900114A/pt not_active Application Discontinuation
-
2001
- 2001-09-26 US US09/963,237 patent/US20020032161A1/en not_active Abandoned
-
2005
- 2005-12-12 JP JP2005357820A patent/JP2006083186A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK0930077T3 (da) | 2003-08-04 |
| DE69813496D1 (de) | 2003-05-22 |
| EP0930077A1 (de) | 1999-07-21 |
| GB9801109D0 (en) | 1998-03-18 |
| BR9900114A (pt) | 2000-05-02 |
| JPH11255646A (ja) | 1999-09-21 |
| EP0930077B1 (de) | 2003-04-16 |
| CA2259699A1 (en) | 1999-07-20 |
| DE69813496T2 (de) | 2003-10-30 |
| PT930077E (pt) | 2003-07-31 |
| ES2194279T3 (es) | 2003-11-16 |
| JP2006083186A (ja) | 2006-03-30 |
| US20020032161A1 (en) | 2002-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE237359T1 (de) | Zyklodextrin-zusammensetzung enthaltend ein avermectin- oder ein milbemycin-derivat | |
| BR9914221B1 (pt) | Derivados de glicopeptídeos e composições farmacêuticas contendo os mesmos | |
| ATE225341T1 (de) | In 6-position durch thio substituierte paclitaxele | |
| DE60104206D1 (de) | Halbfeste arzneizubereitung enthaltend isotretinoin | |
| ES2184293T3 (es) | Composiciones farmaceuticas administrables por via oral que comprenden una benzhidrilpiperazina y una ciclodextrina. | |
| FI925615A0 (fi) | Stabiliserade farmaceutiska kompositioner, som innehaoller en hmg-coa-reduktas-inhibitorfoerening | |
| NO20034149L (no) | Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel | |
| ES2181744T3 (es) | Hidratos de paclitaxel cristalinos. | |
| AR005640A1 (es) | Composiciones endoparasiticidas | |
| BR0215392A (pt) | Composições farmacêuticas compreendendo um inibidor de fosfodiesterase multifuncional e um inibidor de absorção de adenosina, bem como uso das mesmas | |
| ES2129078T3 (es) | Preparacion farmaceutica que comprende un compuesto capaz de degradar los antibioticos beta-lactamicos y su utilizacion. | |
| BR0014775B1 (pt) | misturas antimicrobianas de 1,3-bis (hidroximetil) -5,5-dimetilidantoina e 1,2-benzisotiazolin-3-ona. | |
| CY1105387T1 (el) | Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου | |
| DE69814441D1 (de) | 6,11-verbrückte erythromycinderivate | |
| DE69805165D1 (de) | Isocyanat-vernetzbare, wässrige zusammensetzungen niedrigen gehalts an flüchtigen organischen verbindungen | |
| DE69936153D1 (de) | Biologischaktive Labdan- oder Labdenderivate aus Cistus. | |
| DE69936052D1 (de) | N1 modifizierte glycopeptide | |
| PT1142905E (pt) | Novo composto de depsipeptido | |
| ATE296623T1 (de) | Prolaktin-senkendes mittel | |
| EP0297594A3 (de) | 3',4'-Di-N-substituierte Epipodophyllotoxin-Glucosid-Derivate | |
| ES2173586T3 (es) | Derivados de ciclohexandiol. | |
| DE60117465D1 (de) | Lipide mit aminoxygruppe | |
| NO20020664D0 (no) | Streptomyces Avermitilis gen som bestemmer forholdet B2:B1 avermectiner | |
| ES2126622T3 (es) | Dispositivo de calibracion para la determinacion fotometrica de la bilirrubina. | |
| FI950101A0 (fi) | 4-oksa-1-atsabisyklo 3,2,0 -7heptanoni-johdannaiset kasvainten vastaisina aineina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0930077 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |